NCT03943615 is a clinical trial of Voxelotor in Sickle Cell Disease, sponsored by Pfizer.

Who is sponsoring NCT03943615?

NCT03943615 is sponsored by Pfizer.

What drugs are being tested in NCT03943615?

Interventions in NCT03943615: Voxelotor.

What condition does NCT03943615 study?

NCT03943615 studies Sickle Cell Disease.

Is NCT03943615 still recruiting?

NCT03943615 is currently no longer available. Last updated 18 July 2023.

Last reviewed 2023-07-18 · How we verify

NCT03943615

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

NO LONGER AVAILABLE Last updated 18 July 2023

What this trial tests

trial testing Voxelotor in Sickle Cell Disease. No longer available.

Quick facts

Lead sponsor	Pfizer
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	18 locations across United States

Drugs / interventions tested

Voxelotor (voxelotor) — full drug profile →

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →

Sponsor

Pfizer — full company profile →

Who can join

12 and older, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The intent of this open-label, multicenter expanded access program (EAP) is to provide early access to voxelotor prior to market authorization

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Drug Therapies for the Management of Sickle Cell Disease.
Rai P, Ataga KI. · · 2020 · cited 32× · PMID 32765834 · DOI 10.12688/f1000research.22433.1

Verify or expand the search:

Other trials of Voxelotor

Trials testing the same drug.

NCT06023199 — Assessing Physical Function in Sickle Cell Patients Taking Voxelotor · Phase 2 · active not recruiting
NCT05981365 — Voxelotor CYP and Transporter Cocktail Interaction Study · Phase 1 · completed
NCT05289570 — Voxelotor for Improving Oxygen Saturation in Adults · Phase 2 · terminated
NCT05018728 — The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia · Phase 2 · terminated
NCT04335721 — A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease · Phase 1, PHASE2 · terminated

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03943615 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 18 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03943615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing